U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H17O3S.Na.H2O
Molecular Weight 318.364
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM GUALENATE MONOHYDRATE

SMILES

O.[Na+].CC(C)C1=CC=C(C)C2=C(C=C(C)C2=C1)S([O-])(=O)=O

InChI

InChIKey=MBPDRKMZHLMXCP-UHFFFAOYSA-M
InChI=1S/C15H18O3S.Na.H2O/c1-9(2)12-6-5-10(3)15-13(8-12)11(4)7-14(15)19(16,17)18;;/h5-9H,1-4H3,(H,16,17,18);;1H2/q;+1;/p-1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://aksci.com/item_detail.php?cat=R239 http://www.ncbi.nlm.nih.gov/pubmed/15667596

Sodium gualenate (Azunol ST Tablets) is a water-soluble derivative of azulene, a natural product which is an antiinflammatory component of chamomile of the family of Asteraceae. Sodium gualenate was originally studied as an antiulcer agent, is primary indicated in conditions like Duodenal ulcer, Gastric ulcer, Gastritis, but it is also clinically used as a therapeutic agent in the treatment of inflammation of the mouth and throat, for example, pharyngitis as well as other inflammatory diseases such as tonsillitis, stomatitis and conjunctivitis. Although the mechanism by which sodium azulene sulfonate inhibited the capsaicin-induced pharyngitis is not yet unraveled, antioxidative effect, but not inhibitory effect on cyclooxygenase pathway, might be involved.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukemia].
2003 Sep
The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments.
2005 Dec
Patents

Patents

Sample Use Guides

Put 1 tablet (5 mg of the active ingredient) between either of right or left upper lip and gum at a time, four times daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
SODIUM GUALENATE MONOHYDRATE
Common Name English
SODIUM GUALENATE HYDRATE [JAN]
Common Name English
SODIUM GUALENATE HYDRATE
JAN   WHO-DD  
Common Name English
1-AZULENESULFONIC ACID, 3,8-DIMETHYL-5-(1-METHYLETHYL)-, SODIUM SALT, MONOHYDRATE
Common Name English
1-AZULENESULFONIC ACID, 3,8-DIMETHYL-5-(1-METHYLETHYL)-, SODIUM SALT, HYDRATE (1:1:1)
Common Name English
Sodium gualenate hydrate [WHO-DD]
Common Name English
AZUNOL
Brand Name English
Code System Code Type Description
PUBCHEM
23665552
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
CAS
116277-75-9
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID70151331
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
FDA UNII
ZA7WCE6DK5
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
SMS_ID
100000127422
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
EVMPD
SUB33465
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY